Placenta accreta:adherent placenta due to Asherman syndrome by Engelbrechtsen, L. et al.
Syddansk Universitet
Placenta accreta
adherent placenta due to Asherman syndrome
Engelbrechtsen, L.; Langhoff-Roos, J.; Kjer, J. J.; Istre, Olav
Published in:
Clinical Case Reports
DOI:
10.1002/ccr3.194
Publication date:
2015
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY-NC
Citation for pulished version (APA):
Engelbrechtsen, L., Langhoff-Roos, J., Kjer, J. J., & Istre, O. (2015). Placenta accreta: adherent placenta due to
Asherman syndrome. Clinical Case Reports, 3(3), 175-178. DOI: 10.1002/ccr3.194
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 09. Sep. 2018
CASE REPORT
Placenta accreta: adherent placenta due to Asherman
syndrome
Line Engelbrechtsen1, Jens Langhoff-Roos2, Jens Joergen Kjer1 & Olav Istre3
1Department of Gynaecology, Rigshospitalet, Blegdamsvej 9, Copenhagen 2100, Denmark
2Department of Obstetrics, Rigshospitalet, Blegdamsvej 9, Copenhagen 2100, Denmark
3Department of Obstetrics and Gynaecology, Odense University Hospital Odense, 5000, Denmark
Correspondence
Line Engelbrechtsen, Department of
Gynaecology, Rigshospitalet, Blegdamsvej 9,
Copenhagen, 2100, Denmark. E-mail:
line@engelbrechtsen.info
Funding Information
No funding information provided.
Received: 8 May 2014; Revised: 15 October
2014; Accepted: 25 October 2014
Clinical Case Reports 2015; 3(3): 175–178
doi: 10.1002/ccr3.194
Key Clinical Message
It is important to be aware of the risk of abnormally invasive placenta in
patients with a history of Asherman syndrome and uterine scarring. A prenatal
diagnosis by ultrasonography is useful when planning of mode of delivery.
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Introduction
Asherman syndrome was first reported in 1894 by Hein-
rich Fritz [1]. Asherman syndrome is also known as uter-
ine atresia, amenorrhea traumatica, endometrial sclerosis,
and intrauterine adhesions or synechiae [2]. The preva-
lence of Asherman syndrome varies from 1.55 to 20%
[3–6] according to population, mainly due to different
diagnostic criteria, the number of abortions in the popu-
lation, choice of management, awareness of clinicians,
and incidence of infections (genital tuberculosis and puer-
peral infections) [4].
Asherman syndrome arises due to trauma of the endo-
metrium and produces partial or complete obliteration of
the uterine cavity or/and cervical canal [1, 4, 7, 8].
Trauma of the uterine cavity results in dysfunction of the
endometrium which presents in conditions such as men-
strual abnormalities, dysmenorrhea, infertility, and recur-
rent pregnancy loss [8].
Asherman syndrome can occur due to uterine and
intrauterine surgery such as cesarean section, curettage,
myomectomy involving the uterine cavity, endometrial
ablation, and hysteroscopic removal of fibroids and pol-
yps [4, 7–11]. However, intrauterine adhesions are also
seen as a consequence of endometritis, congenital uterine
abnormalities, and genetic predisposition [2]. It is well-
known that the endometrium is more susceptible to
trauma in a pregnant uterus and the incidence of intra-
uterine adhesions following curettage for retained placen-
tal tissue is reported up to 40% 3 months after curettage
[5]. In patients who develop Asherman syndrome, curet-
tage of a pregnant uterus has been shown as the cause in
64% of the cases. Hysteroscopic adhesiolysis can be an
effective treatment of Asherman syndrome, with an over-
all conception rate of 40% following surgery [12].
Trauma of the endometrium can cause defects in the
basal decidua (Nitabuchs layer) which in a gravid uterus
can give rise to abnormal placentation. Placenta accreta
arises when the anchoring villi of the placenta adheres to
the surface of the myometrium [11, 13].
Placenta accreta is associated with complications during
delivery including life-threatening maternal hemorrhage,
blood transfusions, and subsequent peripartum hysterec-
tomy [9, 10, 14]. Over the last decades an increase in inci-
dence has been reported with a rise from 0.04% to 0.9%,
possibly due to increased rate of uterine surgery [14–17].
We describe a case of placenta accreta in a patient with
a history of Asherman syndrome due to uterine scarring
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after evacuation of retained tissue from a missed abor-
tion.
Case Description
A 38-year-old woman, gravida 3, para 1 presented with a
spontaneous pregnancy. Her previous surgical history
included a cesarean section and a hysteroscopic removal
of uterine synechiae secondary to Asherman syndrome.
One year prior to this pregnancy, the patient had a
missed abortion at 7 weeks of gestational age. Medical
induction with misoprostol was unsuccessful in two
attempts. Due to retained tissue, a surgical evacuation of
the uterus with dilatation and curettage was performed.
In the following months, the patient experienced second-
ary amenorrhea, and the patient was referred for gynecol-
ogist due to suspicion of Asherman syndrome.
A transvaginal ultrasound at day 17 in menstrual cycle
showed thick endometrium disrupted by defects, most
likely due to strictures in the uterus.
Hysterosalpingography was attempted, but not com-
pleted due to the fact that it was not possible to inject
contrast into the uterine cavity. The patient was sched-
uled for hysteroscopic surgery.
Hysteroscopic surgery revealed a wide adherence across
the uterine cavity, just above the internal orifice. A small
defect in the adherence was resected and incisions were
made at position 3, 6, 9, and 12 according to myometrial
scoring [18]. The adhesion was removed and revealed a
uterine cavity covered by endometrium in approximately
50% of the cavity (Figure 1). The uterine scarring was
classified as Asherman syndrome stadium II (ranging
from I to III) according to The American Society for
Reproductive Medicine classification [19]. The patient
received treatment with Progynova (Estradiol valerate)
2 mg twice daily in 4 weeks postoperatively to prevent
recurrence of intrauterine adhesions.
The patient attended postoperatively follow-up 4 weeks
after surgery. A transvaginal ultrasound showed a uterus
with visible endometrium along the whole cavity. A sono-
hysterography was performed to evaluate uterine cavity
and tubal patency and revealed a normal cavity with flow
of saline through both tubes.
The present pregnancy was conceived 2 months after
follow-up. The patient attended first trimester screening
at 12 weeks of gestation. A singleton fetus with normal
nuchal translucency thickness and risk assessment was
found. A routine scan was performed at 22 weeks of ges-
tation and showed no sign of congenital abnormalities.
Placenta was seen on the posterior uterine wall, low
inserted approx. 18 mm from internal ostium (Figure 2).
The myometrium underlying placenta had normal
appearance. The anterior uterine wall was found thin
behind the bladder, measuring 4 mm.
The patient was monitored with ultrasonography every
3–4 weeks due to the previous history of Asherman syn-
drome.
The patient underwent an ultrasound scan at 35 weeks
of gestation where the uterine wall was found thin at the
anterior uterine wall (site of previous cesarean scar) with a
myometrium of 2 mm (Figure 3). Due to risk of uterine
rupture during vaginal delivery, the patient was planned for
cesarean section. The woman had future childbearing
wishes, and was informed that excessive bleeding at delivery
might lead to extensive uterine surgery and possibly hyster-
ectomy.
A cesarean section was performed at 38 weeks of gesta-
tion. During surgery the lower anterior uterine wall was
found very thin, however, without dehiscence. Placenta
was found partly abnormally adherent on the posterior
uterine wall with the appearance of a placenta accreta.
Figure 1. Hysteroscopic image. Uterine cavity with uterine scarring
due to Asherman syndrome.
Figure 2. Transabdominal ultrasound scan at 22 weeks of gestation.
Placenta on posterior wall located 18 mm from internal ostium.
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Manual removal of placenta was performed and bleeding
was measured to approximately 1 liter intraoperatively. A
Bakri balloon was inserted and the bleeding subsided.
There was no need for uterine sutures or hysterectomy.
The Bakri ballon was removed 24 h after the cesarean sec-
tion and the woman was discharged in good condition
2 days postoperatively.
Discussion
Asherman syndrome is seen in women with previous
trauma of the endometrium. The syndrome is well-
known, however, evidence-based guidelines on prevention
and management are lacking.
Dilatation and curettage are known risk factors for
development of Asherman syndrome. Curettage is often
performed due to retained tissue after abortion or deliv-
ery and with the focus entirely on emptying the uterus,
and not on the prognosis for future fertility. Therefore,
curettage is often too coarse and even with preventive
means, such as hormonal treatment or cobber IUD post-
operatively, formation of intrauterine adhesions can still
occur. Therefore, emptying of the uterine cavity after
abortion or delivery should be gentle and performed
under ultrasonic guidance or by hysteroscopy [20].
Following diagnose and treatment of Asherman syn-
drome it is important to prevent formation of new adhe-
sions. Treatment with estrogen has shown good results in
preventing reformation of adhesions following hystero-
scopic surgery for Asherman syndrome. Use of peroral
estrogen gives better fertility and menstrual outcome
when given in combination with ancillary treatment
(IUD, balloon or hyaluronic acid) [21].
A recent study by Roy et al. reported conception rates
of 58% in mild Asherman, 30% in moderate Asherman,
and 33.3% in severe cases of Asherman syndrome follow-
ing hysteroscopic adhesiolysis. Furthermore, the live birth
rate reported was 86.1%, the miscarriage rate 11.1% and
the cumulative pregnancy rate showed that 97.2% of the
patients conceived within 24 months postoperatively [12].
Studies evaluating obstetric complications in pregnant
women with previous Asherman syndrome are sparse. A
number of cases have been reported but large observa-
tional studies are lacking. In 1982, Schenker and Margali-
oth [4] found an incidence of placenta accreta in 13–14%
of patients with previous Asherman syndrome. Roy et al.
[12] reported an incidence of postpartum hemorrhage
due to adherent placenta in 12.5% of the 89 women who
had undergone hysteroscopic adhesiolysis due to Asher-
man syndrome. These numbers present a remarkably low
incidence of abnormal placentation in a group of women,
who all had known trauma of the endometrium (i.e.,
87.5% did not have an adherent placenta and subsequent
postpartum hemorrhage).
This case report describes a patient with a placenta ac-
creta on posterior uterine wall in a pregnancy following
hysteroscopic removal of adhesions due to Asherman syn-
drome. The finding of an adherent placenta intraopera-
tively was unexpected, as the patient had been thoroughly
examined with sonography during pregnancy.
Conventional 2 dimensional ultrasonography is cur-
rently the best screening tool for detecting placenta accre-
ta with a sensitivity of 77–90.7%, a specificity of 96–98%,
a positive predictive value of 65–93%, and a negative pre-
dictive value of 98% [22–24]. Another diagnostic tool for
detection of abnormal placentation is Magnetic Resonance
Imaging (MRI). MRI has a sensitivity of 80–85% and a
specificity of 65–100% [25]. MRI can be used in conjunc-
tion with conventional ultrasonography [26], and can be
helpful in some cases, especially if the placenta is located
on the posterior uterine wall. Though it is important to
notice, that for cases of placenta accreta, MRI is not a
good prognostic tool for changing of surgical manage-
ment [27]. Retrospective studies have shown that women
with an antenatal diagnosis of placenta accreta have less
blood loss and requirement for blood transfusion than
women in whom the abnormal placentation was diag-
nosed during cesarean section [28, 29].
Any patient with a previous history of intrauterine sur-
gery or Asherman syndrome should be thoroughly exam-
ined by a skilled sonographer for possible abnormal
placentation. In case of any suspicion of abnormal placen-
tation, the patient should be scheduled for planned cesar-
ean section with a set-up of skilled clinicians due to risk
of severe postpartum hemorrhage.
In conclusion, it is important to be aware of the risk of
a placenta accreta in patients with a previous history of
Asherman syndrome and uterine scarring. Antenatal
Figure 3. Transabdominal ultrasound scan at 35 weeks of gestation.
Anterior uterine wall is measuring 2 mm at the site of previous
cesarean section.
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diagnosis is important to counsel the pregnant woman
and to plan mode of delivery.
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